Description: Anti-obesity medications have been met with reluctance from payers and employee benefits consultants who often lack analogs or empirical data to estimate the cost impact of new therapies coverage. Health plans considering coverage of anti-obesity medications will need to assess and manage the potential costs of covering these new therapies in context of their overall obesity management strategy, including coverage of nutrition counseling, weight management, and bariatric surgery.

Description: This session will bring together public health care leaders in COVID-10 vaccine delivery from both the U.S. and the UK to discuss and compare operational implications of the COVID-19 vaccine rollout in their countries, and how those programs ultimately affected hospitalization utilization and mortality rates for members of their communities.

Description: This project enhances the current understanding of cyber risks in the smart home ecosystem from the insurance industry's perspective. In particular, the quantitative framework and pricing strategies developed in this project can be immediately adopted/adapted by actuaries to price the cyber risks for smart homes, a fast-growing insurance market.

Description: Medicare Advantage plans have been in the market for two decades. In this session, we survey the landscape changes from 2006 up to now, which include but not limited to the changes of enrollment, plan types, big players' market share, policies, and how players as well as beneficiaries react to the changes. This session intends to provide general MA knowledge and history to the audience with or without Medicare Advantage background.

Description: For decades, drug overdose deaths have been increasing within the U.S., with opioid-related mortality driving this increase. The Society of Actuaries Research Institute (SOA) sponsored this research to investigate the trends and drivers behind drug overdose mortality and substance-related deaths as a whole. Findings provided a range of insights surrounding substance use disorder, drug overdose and alcohol-induced mortality, and considerations for insurers.

Description: Renal disease is a very heterogenous medical condition whose end state is dialysis, a recurring cost intensive medical condition. Dialysis cost is one of the major medical cost drivers in USA. Insufficient and improper care management in the early stages of CKD (chronic kidney disease) leads to early incidence of end stage renal disease (ESRD) among CKD patients which not only leads to high medical costs, but also reflects poor health quality.

Description: This is a study to perform a mortality analysis of the 1898-1902 birth cohort.

Description: Get an in-depth explanation on how data scientists and actuaries can work together to battle the issues arising from big data. Join our focus on the insurance industry as a whole and look at data scientists' and actuaries' roles from the views of different areas of the industry. We will also focus on how data science can be a valuable tool for actuaries. After the session, you will be able to understand: - How developments in data science are shaping Insurance Industry practices - How data scientists can help actuaries - How data science can be used to improve analysis of industry experience

Description: Become informed about the approach and adverse effects of the regulation of third parties and advance consent by the proposed NAIC Consumer Privacy Protection Model Law #674. You will hear an explanation of the regulation of third parties through their contracts with insurers. Learn specifics on the negative effect on companies contracting with third parties. Find out more about the requirement for advance consent for use of personal data for actuarial and marketing studies, and hear two potential solutions .At the conclusion of this session, you should be able to explain concerns about contracting with third parties for external data under the Model Law and learn potential solutions to using personal data for actuarial and marketing studies.

Description: This report documents updates to the Canadian mortality data in both the Human Mortality Database and the Canadian Human Mortality Database, including new data for 2022–2023.